BioLineRx Ltd.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $68.1M | $13.0M |
| FY2022 | — | $50.8M | $10.6M |
| FY2023 | — | $13.2M | $4.3M |
| FY2024 | — | $13.5M | $10.4M |
| FY2025 | — | $18.2M | $3.3M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $68.1M | $13.0M |
| FY2022 | — | $50.8M | $10.6M |
| FY2023 | — | $13.2M | $4.3M |
| FY2024 | — | $13.5M | $10.4M |
| FY2025 | — | $18.2M | $3.3M |